Literature DB >> 27884224

The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome.

Peminda K Cabandugama1, Michael J Gardner1, James R Sowers2.   

Abstract

In the United States, more than 50 million people have blood pressure at or above 120/80 mm Hg. All components of cardiorenal metabolic syndrome (CRS) are linked to metabolic abnormalities and obesity. A major driver for CRS is obesity. Current estimates show that many of those with hypertension and CRS show some degree of systemic and cardiovascular insulin resistance. Several pathophysiologic factors participate in the link between hypertension and CRS. This article updates recent literature with a focus on the function of insulin resistance, obesity, and renin angiotensin aldosterone system-mediated oxidative stress on endothelial dysfunction and the pathogenesis of hypertension. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adipocyte; Angiotensin II; Hypertension; Insulin resistance; Obesity

Mesh:

Substances:

Year:  2017        PMID: 27884224      PMCID: PMC5125542          DOI: 10.1016/j.mcna.2016.08.009

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  41 in total

Review 1.  The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

Authors:  Stefan Engeli; Petra Schling; Kerstin Gorzelniak; Michael Boschmann; Jürgen Janke; Gérard Ailhaud; Michèle Teboul; Florence Massiéra; Arya M Sharma
Journal:  Int J Biochem Cell Biol       Date:  2003-06       Impact factor: 5.085

2.  Angiotensin converting enzyme inhibition improves cardiac neuronal uptake of noradrenaline in spontaneously hypertensive rats.

Authors:  W Raasch; S Betge; A Dendorfer; T Bartels; P Dominiak
Journal:  J Hypertens       Date:  2001-10       Impact factor: 4.844

Review 3.  The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Authors:  Kaberi Dasgupta; Robert R Quinn; Kelly B Zarnke; Doreen M Rabi; Pietro Ravani; Stella S Daskalopoulou; Simon W Rabkin; Luc Trudeau; Ross D Feldman; Lyne Cloutier; Ally Prebtani; Robert J Herman; Simon L Bacon; Richard E Gilbert; Marcel Ruzicka; Donald W McKay; Tavis S Campbell; Steven Grover; George Honos; Ernesto L Schiffrin; Peter Bolli; Thomas W Wilson; Patrice Lindsay; Michael D Hill; Shelagh B Coutts; Gord Gubitz; Mark Gelfer; Michel Vallée; G V Ramesh Prasad; Marcel Lebel; Donna McLean; J Malcolm O Arnold; Gordon W Moe; Jonathan G Howlett; Jean-Martin Boulanger; Pierre Larochelle; Lawrence A Leiter; Charlotte Jones; Richard I Ogilvie; Vincent Woo; Janusz Kaczorowski; Kevin D Burns; Robert J Petrella; Swapnil Hiremath; Alain Milot; James A Stone; Denis Drouin; Kim L Lavoie; Maxime Lamarre-Cliche; Guy Tremblay; Pavel Hamet; George Fodor; S George Carruthers; George B Pylypchuk; Ellen Burgess; Richard Lewanczuk; George K Dresser; S Brian Penner; Robert A Hegele; Philip A McFarlane; Milan Khara; Andrew Pipe; Paul Oh; Peter Selby; Mukul Sharma; Debra J Reid; Sheldon W Tobe; Raj S Padwal; Luc Poirier
Journal:  Can J Cardiol       Date:  2014-02-22       Impact factor: 5.223

Review 4.  Insulin resistance and skeletal muscle vasculature: significance, assessment and therapeutic modulators.

Authors:  Camila Manrique; James R Sowers
Journal:  Cardiorenal Med       Date:  2014-12-02       Impact factor: 2.041

5.  Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects.

Authors:  M Ozata; I C Ozdemir; J Licinio
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

6.  Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index.

Authors:  T Kazumi; A Kawaguchi; J Katoh; M Iwahashi; G Yoshino
Journal:  J Hypertens       Date:  1999-10       Impact factor: 4.844

7.  Mechanisms mediating renal sympathetic activation to leptin in obesity.

Authors:  Donald A Morgan; Daniel R Thedens; Robert Weiss; Kamal Rahmouni
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-09-24       Impact factor: 3.619

8.  Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.

Authors:  Ulrich Kintscher; Peter Bramlage; W Dieter Paar; Martin Thoenes; Thomas Unger
Journal:  Cardiovasc Diabetol       Date:  2007-04-03       Impact factor: 9.951

Review 9.  Leptin and hypertension in obesity.

Authors:  Paco E Bravo; Stephen Morse; David M Borne; Erwin A Aguilar; Efrain Reisin
Journal:  Vasc Health Risk Manag       Date:  2006

Review 10.  Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?

Authors:  Shawn B Bender; Adam P McGraw; Iris Z Jaffe; James R Sowers
Journal:  Diabetes       Date:  2013-02       Impact factor: 9.461

View more
  43 in total

1.  Smooth Muscle Cell-Specific Disruption of the BBSome Causes Vascular Dysfunction.

Authors:  John J Reho; Deng-Fu Guo; Donald A Morgan; Kamal Rahmouni
Journal:  Hypertension       Date:  2019-08-19       Impact factor: 10.190

2.  The effect of a multidisciplinary weight loss program on renal circadian rhythm in obese adolescents.

Authors:  Kim Pauwaert; Sarah Dejonckheere; Elke Bruneel; Jolien Van Der Jeugt; Laura Keersmaekers; Saskia Roggeman; Ann De Guchtenaere; Johan Vande Walle; Karel Everaert
Journal:  Eur J Pediatr       Date:  2019-09-05       Impact factor: 3.183

Review 3.  The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications.

Authors:  Amanda J Miller; Amy C Arnold
Journal:  Clin Auton Res       Date:  2018-11-09       Impact factor: 4.435

Review 4.  Arterial Stiffness in Hypertension: an Update.

Authors:  Korshie Dumor; Michael Shoemaker-Moyle; Ravi Nistala; Adam Whaley-Connell
Journal:  Curr Hypertens Rep       Date:  2018-07-04       Impact factor: 5.369

Review 5.  Obesity, kidney dysfunction and hypertension: mechanistic links.

Authors:  John E Hall; Jussara M do Carmo; Alexandre A da Silva; Zhen Wang; Michael E Hall
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

Review 6.  Thick Ascending Limb Sodium Transport in the Pathogenesis of Hypertension.

Authors:  Agustin Gonzalez-Vicente; Fara Saez; Casandra M Monzon; Jessica Asirwatham; Jeffrey L Garvin
Journal:  Physiol Rev       Date:  2019-01-01       Impact factor: 37.312

Review 7.  Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery.

Authors:  Omair A Shariq; Travis J McKenzie
Journal:  Gland Surg       Date:  2020-02

8.  Dietary Fat and Sugar Differentially Affect β-Adrenergic Stimulation of Cardiac ERK and AKT Pathways in C57BL/6 Male Mice Subjected to High-Calorie Feeding.

Authors:  Sadia Ashraf; Gizem Yilmaz; Xu Chen; Romain Harmancey
Journal:  J Nutr       Date:  2020-05-01       Impact factor: 4.798

Review 9.  Obesity, inflammation, and heart failure: links and misconceptions.

Authors:  Filippos Triposkiadis; Andrew Xanthopoulos; Randall C Starling; Efstathios Iliodromitis
Journal:  Heart Fail Rev       Date:  2021-04-07       Impact factor: 4.214

10.  mTORC1 (Mechanistic Target of Rapamycin Complex 1) Signaling in Endothelial and Smooth Muscle Cells Is Required for Vascular Function.

Authors:  John J Reho; Deng-Fu Guo; Donald A Morgan; Kamal Rahmouni
Journal:  Hypertension       Date:  2020-12-28       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.